Skip to main content Accessibility help
×
Hostname: page-component-7c8c6479df-7qhmt Total loading time: 0 Render date: 2024-03-28T13:24:42.222Z Has data issue: false hasContentIssue false

20 - The management of infection in myeloma

from Section 4 - Supportive therapies

Published online by Cambridge University Press:  18 December 2013

Stephen A. Schey
Affiliation:
Department of Haematology, King’s College Hospital, London
Kwee L. Yong
Affiliation:
Department of Haematology, University College Hospital, London
Robert Marcus
Affiliation:
Department of Haematology, King’s College Hospital, London
Kenneth C. Anderson
Affiliation:
Dana-Farber Cancer Institute, Boston
Get access

Summary

Introduction

Myeloma is primarily a disease of older age groups with the median age of diagnosis above 60 years. Although, in the past, the prognosis was poor, this has changed over the past decade with the advent of new therapies and the use of autologous stem cell transplantation. Whereas formerly the infective problems associated with myeloma were the consequence of the disease itself and were often the mode of presentation, now the disease can be viewed as more chronic and infections are more commonly related to either the therapies used or the longer term complications of myeloma itself. Nevertheless, infections still account for the majority of deaths in the first 120 days after diagnosis. This chapter will address the risk factors for infection in myeloma and will outline the more common infective complications and their management, as well as considering what preventive measures can be taken.

Risk factors for infection

Immunodeficiency

The hallmark of myeloma is B cell dysregulation, usually manifested by hypogammaglobulinemia. This leads to an increased risk of bacterial infections, particularly those due to encapsulated organisms such as Streptococcus pneumoniae and Haemophilus influenzae. Other common bacterial infections that may present early on are Staphylococcus aureus and Eschericia coli[1]. However, there is ample evidence that the disease also affects cellular immunity with abnormalities of T lymphocytes, dendritic cells and NK cells. Although the cellular defects may be more subtle and do not normally manifest early in myeloma, they undoubtedly contribute to some of the complications of chemotherapy[2].

Type
Chapter
Information
Myeloma
Pathology, Diagnosis, and Treatment
, pp. 276 - 287
Publisher: Cambridge University Press
Print publication year: 2013

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Augustson, B. M., Begum, G., Dunn, J. A. et al. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002–Medical Research Council Adult Leukaemia Working Party. J. Clin. Oncol. 2005;23(36):9219–26.CrossRefGoogle Scholar
Schutt, P., Brandhorst, D., Stellberg, W. et al. Immune parameters in multiple myeloma patients: influence of treatment and correlation with opportunistic infections. Leuk. Lymphoma 2006;47(8):1570–82.CrossRefGoogle ScholarPubMed
Engelich, G., Wright, D. G., Hartshorn, K. L.Acquired disorders of phagocyte function complicating medical and surgical illnesses. Clin. Infect. Dis. 2001;33(12):2040–8.CrossRefGoogle ScholarPubMed
Wimalawansa, S. J.Bisphosphonate-associated osteomyelitis of the jaw: guidelines for practicing clinicians. Endocr. Pract. 2008;14(9):1150–68.CrossRefGoogle ScholarPubMed
Chanan-Khan, A., Sonneveld, P., Schuster, M. W. et al. Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J. Clin. Oncol. 2008;26(29):4784–90.CrossRefGoogle ScholarPubMed
Basler, M., Lauer, C., Beck, U., Groettrup, M.The proteasome inhibitor bortezomib enhances the susceptibility to viral infection. J. Immunol. 2009;183(10):6145–50.CrossRefGoogle ScholarPubMed
Costa, D. B., Shin, B., Cooper, D. L.Pneumococcemia as the presenting feature of multiple myeloma. Am. J. Hematol. 2004;77(3):277–81.CrossRefGoogle ScholarPubMed
Tleyjeh, I. M., Tlaygeh, H. M., Hejal, R., Montori, V. M., Baddour, L. M.The impact of penicillin resistance on short-term mortality in hospitalized adults with pneumococcal pneumonia: a systematic review and meta-analysis. Clin. Infect. Dis. 2006;42(6):788–97.CrossRefGoogle ScholarPubMed
Baddour, L. M., Yu, V. L., Klugman, K. P. et al. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am. J. Respir. Crit. Care. Med. 2004;170(4):440–4.CrossRefGoogle ScholarPubMed
Arnan, M., Gudiol, C., Calatayud, L. et al. Risk factors for, and clinical relevance of, faecal extended-spectrum beta-lactamase producing Escherichia coli (ESBL-EC) carriage in neutropenic patients with haematological malignancies. Eur. J. Clin. Microbiol. Infect. Dis. 2011;30(3):355–60.CrossRefGoogle ScholarPubMed
Kelly, C. P., LaMont, J. T.Clostridium difficile – more difficult than ever. N. Engl. J. Med. 2008;359(18):1932–40.CrossRefGoogle Scholar
Chopra, T., Chandrasekar, P., Salimnia, H. et al. Recent epidemiology of Clostridium difficile infection during hematopoietic stem cell transplantation. Clin. Transplant 2011;25(1):E82–7.CrossRefGoogle ScholarPubMed
Freifeld, A. G., Bow, E. J., Sepkowitz, K. A. et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America. Clin. Infect. Dis. 2011;52(4):e56–93.CrossRefGoogle ScholarPubMed
Moores, K. G.Safe and effective outpatient treatment of adults with chemotherapy-induced neutropenic fever. Am. J. Health. Syst. Pharm. 2007;64(7):717–22.CrossRefGoogle ScholarPubMed
Marr, K. A., Carter, R. A., Boeckh, M., Martin, P., Corey, L.Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002;100(13):4358–66.CrossRefGoogle ScholarPubMed
Mori, Y., Nagasaki, Y., Kamezaki, K. et al. High incidence of false-positive Aspergillus galactomannan test in multiple myeloma. Am. J. Hematol. 2010;85(6):449–51.Google ScholarPubMed
Pappas, P. G., Kauffman, C. A., Andes, D. et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 2009;48(5):503–35.CrossRefGoogle ScholarPubMed
Lortholary, O., Ascioglu, S., Moreau, P. et al. Invasive aspergillosis as an opportunistic infection in nonallografted patients with multiple myeloma: a European Organization for Research and Treatment of Cancer/ Invasive Fungal Infections Cooperative Group and the Intergroupe Francais du Myelome. Clin. Infect. Dis. 2000;30(1):41–6.CrossRefGoogle ScholarPubMed
Segal, B. H.Aspergillosis. N. Engl. J. Med. 2009;360(18):1870–84.CrossRefGoogle ScholarPubMed
Panackal, A. A., Li, H., Kontoyiannis, D. P. et al. Geoclimatic influences on invasive aspergillosis after hematopoietic stem cell transplantation. Clin. Infect. Dis. 2010;50(12):1588–97.CrossRefGoogle ScholarPubMed
Cordonnier, C., Pautas, C., Maury, S. et al. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clin. Infect. Dis. 2009;48(8):1042–51.CrossRefGoogle ScholarPubMed
Sun, H. Y., Singh, N.Mucormycosis: its contemporary face and management strategies. Lancet. Infect. Dis. 2011;11(4):301–11.CrossRefGoogle ScholarPubMed
Hahn-Ast, C., Glasmacher, A., Muckter, S. et al. Overall survival and fungal infection-related mortality in patients with invasive fungal infection and neutropenia after myelosuppressive chemotherapy in a tertiary care centre from 1995 to 2006. J. Antimicrob. Chemother. 2010;65(4):761–8.CrossRefGoogle Scholar
Roblot, F., Le Moal, G., Godet, C. et al. Pneumocystis carinii pneumonia in patients with hematologic malignancies: a descriptive study. J. Infect. 2003;47(1):19–27.CrossRefGoogle ScholarPubMed
Saag, M. S., Graybill, R. J., Larsen, R. A. et al. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin. Infect. Dis. 2000;30(4):710–18.CrossRefGoogle ScholarPubMed
Fassas, A. B., Bolanos-Meade, J., Buddharaju, L. N. et al. Cytomegalovirus infection and non-neutropenic fever after autologous stem cell transplantation: high rates of reactivation in patients with multiple myeloma and lymphoma. Br. J. Haematol. 2001;112(1):237–41.CrossRefGoogle ScholarPubMed
Kroger, N., Zabelina, T., Kruger, W. et al. Patient cytomegalovirus seropositivity with or without reactivation is the most important prognostic factor for survival and treatment-related mortality in stem cell transplantation from unrelated donors using pretransplant in vivo T-cell depletion with anti-thymocyte globulin. Br. J. Haematol. 2001;113(4):1060–71.CrossRefGoogle ScholarPubMed
Boeckh, M., Ljungman, P.How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood 2009;113(23):5711–19.CrossRefGoogle ScholarPubMed
Zerr, D. M., Fann, J. R., Breiger, D. et al. HHV-6 reactivation and its effect on delirium and cognitive functioning in hematopoietic cell transplantation recipients. Blood 2011;117(19):5243–9.CrossRefGoogle ScholarPubMed
Matsue, K., Aoki, T., Odawara, J. et al. High risk of hepatitis B-virus reactivation after hematopoietic cell transplantation in hepatitis B core antibody-positive patients. Eur. J. Haematol. 2009;83(4):357–64.CrossRefGoogle ScholarPubMed
Derouin, F., Pelloux, H.Prevention of toxoplasmosis in transplant patients. Clin. Microbiol. Infect. 2008;14(12):1089–101.CrossRefGoogle ScholarPubMed
Orlent, H., Crawley, C., Cwynarski, K., Dina, R., Apperley, J.Strongyloidiasis pre and post autologous peripheral blood stem cell transplantation. Bone. Marrow. Transplant 2003;32(1):115–17.CrossRefGoogle ScholarPubMed
Cesana, C., Nosari, A. M., Klersy, C. et al. Risk factors for the development of bacterial infections in multiple myeloma treated with two different vincristine-adriamycin-dexamethasone schedules. Haematologica 2003;88(9):1022–8.Google ScholarPubMed
Straka, C., Sandherr, M., Salwender, H. et al. Testing G-CSF responsiveness predicts the individual susceptibility to infection and consecutive treatment in recipients of high-dose chemotherapy. Blood 2011;117(7):2121–8.CrossRefGoogle ScholarPubMed
Vickrey, E., Allen, S., Mehta, J., Singhal, S.Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy. Cancer 2009;115(1):229–32.CrossRefGoogle ScholarPubMed
Ayala, E., Greene, J., Sandin, R. et al. Valganciclovir is safe and effective as pre-emptive therapy for CMV infection in allogeneic hematopoietic stem cell transplantation. Bone. Marrow. Transplant 2006;37(9):851–6.CrossRefGoogle ScholarPubMed
Cornely, O. A., Maertens, J., Winston, D. J. et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N. Engl. J. Med. 2007;356(4):348–59.CrossRefGoogle ScholarPubMed
Chapel, H. M., Lee, M., Hargreaves, R., Pamphilon, D. H., Prentice, A. G.Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK Group for Immunoglobulin Replacement Therapy in Multiple Myeloma. Lancet 1994;343(8905):1059–63.CrossRefGoogle Scholar
Raanani, P., Gafter-Gvili, A., Paul, M. et al. Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and meta-analysis. Leuk. Lymphoma 2009;50(5):764–72.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×